This study is for people with advanced melanoma (a type of skin cancer) that has worsened after previous treatments with anti-PD-1 and anti-CTLA-4 drugs. It compares a new combination treatment, Vusolimogene Oderparepvec (a genetically modified virus) with nivolumab (an anti-PD-1 antibody), against standard treatments chosen by your doctor. These standard treatments could include nivolumab plus relatlimab, pembrolizumab (another anti-PD-1 antibody), or certain chemotherapy drugs. The study aims to see if the new combination helps people live longer. You can join if you are 12 years or older and have unresectable or metastatic Stage IIIb through IV melanoma. The study plans to enroll about 400 participants.

Study design

This is a randomized, controlled, open-label Phase 3 study, meaning participants are randomly assigned to a treatment group, and both you and your doctor will know which treatment you are receiving. Approximately 400 people will participate.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your overall survival will be assessed up to January 2029, which is approximately 55 months after the study begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.